SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor during the post-trial period, they wrote in the New ...

Use vs non-use of sodium-glucose cotransporter 2 inhibitors by older patients with CKD stages 4-5D is significantly associated with reductions in all-cause mortality risk at 6, 12, and 60 months.